Yildirim F.Ozbakkaloglu A.Ozturk T.Tetik O.2024-07-222024-07-22201600034975http://akademikarsiv.cbu.edu.tr:4000/handle/123456789/15952We describe a patient with severe hemophilia A and Marfan syndrome who underwent an elective Bentall operation. Because of the severe hemophilia, anticoagulation could not be given postoperatively; thus, a biologic Valsalva conduit graft was used. During the procedure, factor VIII was given as a bolus dose just before incision, then by continous infusion intraoperatively to maintain the factor VIII activity level between 200% and 300%. Minimal postoperative bleeding occurred. The infusion was continued postoperatively at a lower dose until all chest tubes, pacing wires, and invasive catheters were removed. The patient was discharged on postoperative day 7 without adverse events. © 2016 The Society of Thoracic Surgeons.EnglishAll Open Access; Bronze Open AccessAdultAortographyBiological ProductsBlood Vessel ProsthesisCardiovascular Surgical ProceduresElective Surgical ProceduresFollow-Up StudiesHeart Valve ProsthesisHemophilia AHumansMaleMarfan SyndromeProsthesis Designblood clotting factor 8 concentratebiological productadultanticoagulationaorta valve regurgitationaorta valve replacementArticleascending aorta surgerybentall operationcardiopulmonary bypasscase reportcomposite graftcomposite materialcomputed tomographic angiographydisease severitydrug dose increaseechocardiographyelective surgeryfunnel chestheart surgeryhemophilia AhumanmaleMarfan syndromeoutcome assessmentphysical examinationpostoperative hemorrhagepostoperative periodpriority journalsurgical drainagesurgical techniquetreatment planningaortographyblood vessel prosthesiscardiovascular surgerycomplicationfollow upheart valve prosthesishemophilia AMarfan syndromeproceduresprosthesis designArticle10.1016/j.athoracsur.2015.09.011